Radko-Juettner, Sandi
Yue, Hong
Myers, Jacquelyn A.
Carter, Raymond D. http://orcid.org/0000-0002-9226-9159
Robertson, Alexis N.
Mittal, Priya
Zhu, Zhexin
Hansen, Baranda S. http://orcid.org/0000-0003-2299-650X
Donovan, Katherine A. http://orcid.org/0000-0002-8539-5106
Hunkeler, Moritz http://orcid.org/0000-0003-0246-1188
Rosikiewicz, Wojciech http://orcid.org/0000-0001-7031-3430
Wu, Zhiping
McReynolds, Meghan G. http://orcid.org/0000-0001-7249-6314
Roy Burman, Shourya S. http://orcid.org/0000-0001-9274-9104
Schmoker, Anna M.
Mageed, Nada http://orcid.org/0009-0005-0046-6104
Brown, Scott A.
Mobley, Robert J.
Partridge, Janet F. http://orcid.org/0000-0003-1102-6305
Stewart, Elizabeth A. http://orcid.org/0000-0001-8005-0427
Pruett-Miller, Shondra M. http://orcid.org/0000-0002-3793-585X
Nabet, Behnam http://orcid.org/0000-0002-6738-4200
Peng, Junmin http://orcid.org/0000-0003-0472-7648
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Fischer, Eric S. http://orcid.org/0000-0001-7337-6306
Roberts, Charles W. M. http://orcid.org/0000-0003-1135-1896
Article History
Received: 18 October 2022
Accepted: 28 February 2024
First Online: 27 March 2024
Change Date: 29 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-024-07402-3
Competing interests
: C.W.M.R. is a scientific advisory board member of Exo Therapeutics, unrelated to this Article. E.S.F. is a founder, scientific advisory board member and equity holder of Civetta Therapeutics, Neomorph (also board member) and Proximity Therapeutics, scientific advisory board member and equity holder in Avilar Therapeutics and Photys Therapeutics, equity holder in Lighthorse Therapeutics and is a consultant to Novartis, Sanofi, EcoR1 capital, Ajax Therapeutics and Deerfield. The E.S.F. laboratory receives or has received research funding from Astellas, Novartis, Ajax, Voronoi, Interline and Deerfield on topics unrelated to this manuscript. B.N. is listed as an inventor on patent applications related to the dTAG system (WO/2017/024318, WO/2017/024319, WO/2018/148440 and WO/2018/148443). B.N. and N.S.G. are inventors on a patent related to the dTAG system and molecules described in this Article (WO/2020/146250). N.S.G. is a founder, science advisory board member and equity holder in Syros, C4 Therapeutics, Allorion, Lighthorse, Voronoi, Inception, Matchpoint, CobroVentures, GSK (scientific advisory board member), Larkspur (board member), Shenandoah (board member) and Soltego (board member). The N.S.G. laboratory receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Arbella, Deerfield and Sanofi on topics unrelated to this Article. K.A.D. is a consultant to Kronos Bio and Neomorph. The other authors declare no competing interests.